DCT

2:26-cv-12588

Takeda Pharmaceutical Co Ltd v. Annora Pharma Pvt Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-12588, D.N.J., 09/23/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey based on Defendant's business of developing, marketing, and selling generic drug products throughout the United States, including in New Jersey. The complaint further asserts that the district is a likely destination for the accused generic product and that Defendant has previously consented to personal jurisdiction in the district in other patent cases.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA, seeking approval to market a generic version of Plaintiff's drug LIVTENCITY® (maribavir), constitutes an act of patent infringement.
  • Technical Context: The lawsuit concerns a pharmaceutical method patent for the antiviral drug maribavir, which is used to treat cytomegalovirus (CMV) infections in post-transplant patients.
  • Key Procedural History: This action was triggered by Defendant's submission of ANDA No. 221113 to the FDA. The patent-in-suit is subject to a terminal disclaimer and is part of a large family of patents and applications stemming from a 2011 application. The complaint notes that Defendant has been a party to numerous prior patent litigations in the District of New Jersey.

Case Timeline

Date Event
2010-10-28 ’368 Patent Priority Date
2026-06-23 ’368 Patent Issue Date
2026-09-23 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,661,368 - "Maribavir Isomers, Compositions, Methods of Making and Methods of Using"

  • Patent Identification: U.S. Patent No. 12,661,368 ("the ’368 Patent"), "Maribavir Isomers, Compositions, Methods of Making and Methods of Using," issued June 23, 2026.

The Invention Explained

  • Problem Addressed: The patent’s background section describes the "unexpected discovery that maribavir may isomerize under in vivo conditions" into other molecular forms that may have lower biological activity ’368 Patent, col. 2:63-65 ’368 Patent, col. 2:21-29 This isomerization is believed to dilute the effective concentration of the drug, reducing its therapeutic efficacy. The patent suggests this phenomenon may explain the failure of a prior Phase 3 clinical trial (the "300 Study"), which allowed dosing under "fed conditions" that may have promoted such isomerization ’368 Patent, col. 2:30-62
  • The Patented Solution: The invention claims to solve this problem by providing specific methods of using maribavir that mitigate isomerization and enhance the drug's bioavailability and efficacy ’368 Patent, abstract ’368 Patent, col. 3:9-15 The patented methods involve administering a specific dose (400 mg twice daily) in an "immediate release formulation," which is functionally defined as releasing the drug within 60 minutes, to ensure a sufficient concentration of the active compound is achieved in the body ’368 Patent, col. 7:16 - col. 8:20
  • Technical Importance: This technical approach provides a method for improving the clinical effectiveness of maribavir by controlling for an in-vivo chemical transformation, thereby potentially rescuing a promising antiviral drug for a vulnerable patient population ’368 Patent, col. 2:36-47 ’368 Patent, col. 3:9-15

Key Claims at a Glance

  • The complaint asserts infringement of "one or more claims" of the ’368 Patent Compl. ¶29 The patent contains two independent claims.
  • Independent Claim 1: A method for treating a CMV infection by orally administering 400 mg of maribavir twice a day, where the compound is in an "immediate release formulation" that "releases said compound from said formulation by dissolution in less than 60 minutes." ’368 Patent, col. 7:16 - col. 8:8
  • Independent Claim 2: A method for treating a CMV infection by orally administering 400 mg of maribavir twice a day, where the compound is in an "immediate release formulation" that "releases said compound from said formulation in vivo in less than 60 minutes following administration." ’368 Patent, col. 8:9-20
  • The patent contains no dependent claims.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Annora’s ANDA Product," identified as "maribavir tablets, 200 mg" for which Annora submitted ANDA No. 221113 seeking FDA approval Compl. ¶22

Functionality and Market Context

The product is intended to be a generic version of Takeda's LIVTENCITY®, an approved drug indicated for treating post-transplant CMV infection in certain patients Compl. ¶5 Compl. ¶25 The complaint is based on the statutory act of infringement under 35 U.S.C. § 271(e)(2), which arises from the submission of an ANDA for a patented drug Compl. ¶27 The core of the infringement allegation rests on the premise that the FDA-approved labeling for LIVTENCITY®, which Annora's generic product would adopt, "instructs and encourages" administration in a manner that practices the methods claimed in the ’368 Patent Compl. ¶8

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

The complaint does not contain a claim chart or detailed, element-by-element infringement allegations. The infringement theory is based on the filing of ANDA No. 221113 as a statutory act of infringement under 35 U.S.C. § 271(e)(2) Compl. ¶27 For post-approval infringement, the theory is one of induced infringement, where the proposed product label for Annora’s ANDA Product will allegedly instruct healthcare providers and patients to use the generic drug in a way that directly infringes the method claims of the ’368 Patent Compl. ¶8 Compl. ¶30

Because Annora’s product is a 200 mg tablet Compl. ¶22, Plaintiff's infringement theory suggests that the label will instruct patients to take two tablets twice a day to achieve the "400 mg twice a day" dosage recited in the claims. The theory further presumes that Annora's product, as a generic equivalent to LIVTENCITY®, will be an "immediate release formulation" that meets the release-rate limitations of the claims.

  • Identified Points of Contention:
    • Scope Questions: A central question will be whether the administration instructions in the proposed label for Annora's 200 mg tablets direct a use that falls within the scope of the claimed "400 mg twice a day" method.
    • Technical Questions: A key factual dispute may arise over whether Annora's ANDA product qualifies as an "immediate release formulation" that meets the specific functional limitations of Claim 1 ("dissolution in less than 60 minutes") or Claim 2 ("in vivo in less than 60 minutes"). As an ANDA filer, Annora must demonstrate that its product is bioequivalent to LIVTENCITY®, and the characteristics of the LIVTENCITY® formulation will be central to this inquiry.

V. Key Claim Terms for Construction

  • The Term: "immediate release formulation"

    • Context and Importance: This term is critical as it defines the drug delivery system required by both independent claims. The patent’s narrative hinges on using a specific formulation type to avoid the isomerization problems of prior studies. Practitioners may focus on this term because its construction will determine whether Annora's generic product, designed to be bioequivalent to LIVTENCITY®, falls within the claims' scope.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification provides a functional definition: an "immediate release" formulation is one where "release of drug from drug formulation by dissolution is less than 60 minutes or is otherwise release from the drug formulation in less than 60 minutes" ’368 Patent, col. 5:31-34 This language may support a broad, purely time-based definition.
      • Evidence for a Narrower Interpretation: The claims themselves provide two distinct definitions. Claim 1 uses an in vitro standard ("by dissolution"), while Claim 2 uses an in vivo standard. A party could argue that the term's meaning is tied to these specific contexts and that one cannot be used to interpret the other. A defendant could also argue that the term must be construed in light of the patent's stated objective of avoiding in-vivo isomerization, potentially limiting it to formulations proven to achieve that goal.

  • The Term: "releases said compound from said formulation in vivo in less than 60 minutes following administration" (from Claim 2)

    • Context and Importance: This limitation distinguishes Claim 2 from Claim 1 and requires proof of the drug's behavior within the human body, not just in a lab test. Its construction is vital because it sets a different, and potentially more complex, standard for infringement.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: A party may argue this is a standard pharmacokinetic parameter that is well understood in the art, referring to the time required for the drug to be released from its dosage form into the body for absorption, and should be given its plain and ordinary meaning.
      • Evidence for a Narrower Interpretation: A defendant may question whether the patent provides sufficient guidance on how to measure this in vivo release with the precision required by the claim (i.e., "in less than 60 minutes"), potentially raising an indefiniteness challenge under 35 U.S.C. § 112. The specification does not appear to detail a specific protocol for measuring this parameter.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement under 35 U.S.C. § 271(b), stating that Annora's product label will intentionally encourage and instruct healthcare professionals and patients to perform the patented method Compl. ¶8 Compl. ¶30 It is alleged that Annora has "knowledge of the '368 patent" and its infringement Compl. ¶30 The complaint also pleads contributory infringement under § 271(c), alleging the ANDA product is "especially adapted" for an infringing use and has "no substantial non-infringing use" Compl. ¶31
  • Willful Infringement: The complaint does not use the word "willful" but does allege the case is "exceptional" and requests attorneys' fees under 35 U.S.C. § 285 Compl. ¶33 The basis for this appears to be the allegation that Annora acted with knowledge of the ’368 Patent when filing its ANDA Compl. ¶30

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of induced infringement: does the proposed product label for Annora’s generic 200 mg tablets necessarily instruct users to administer the drug in a manner that practices every step of the claimed "400 mg twice a day" method, including the "immediate release" limitations?
  • A second key issue will center on claim scope and evidence: how will the court construe the distinct in vitro ("dissolution") and in vivo release limitations in Claims 1 and 2, and what scientific evidence will be required to prove that Annora’s ANDA product meets these functional requirements?
  • A third question relates to validity: will the patent's claims to a specific dosing and formulation method be found valid in light of prior art, including the very clinical studies the patent cites as having failed? The patent's reliance on a failed study as a basis for its invention may become a central point of dispute.